Tibric acid

Tibric acid
Names
	Preferred IUPAC name 2-Chloro-5-[(3R,5S)-3,5-dimethylpiperidine-1-sulfonyl]benzoic acid
Identifiers
CAS Number	37087-94-8;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2104748;
ChemSpider	29975;
ECHA InfoCard	100.048.479
EC Number	253-344-0;
KEGG	D06133;
PubChem CID	32335;
UNII	LK312SQ24Z;
CompTox Dashboard (EPA)	DTXSID1020277 ;
	InChI InChI=1S/C14H18ClNO4S/c1-9-5-10(2)8-16(7-9)21(19,20)11-3-4-13(15)12(6-11)14(17)18/h3-4,6,9-10H,5,7-8H2,1-2H3,(H,17,18)/t9-,10+ Key: IFXSWTIWFGIXQO-AOOOYVTPSA-N;
	SMILES C[C@@H]1C[C@@H](CN(C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)C(=O)O)C;
Properties
Chemical formula	C14H18ClNO4S
Molar mass	331.81 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Tibric acid is a sulfamylbenzoic acid that acts as a hypolipidemic agent. Although it was found to be more powerful than clofibrate in lowering lipid levels, it was found to cause liver cancer in mice and rats, and so was not introduced as a human drug. In rats it causes an increase in peroxisomes, and liver enlargement, and then liver cancer. However the peroxisome changes do not occur in humans, and it is not likely to cause liver cancer in humans.